Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIK2 | Q9H0K1 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | SIK1 | P57059 | 1/20 | 1.00 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 1.00 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.48 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 5/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | PLK1 | P53350 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450843 | 1.00 | SIK2 (1.00) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL30309489 | 1.00 | SIK2 (1.00) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL21479301 | 0.96 | SIK2 (0.92) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL25882204 | 0.95 | SIK2 (0.91) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL21479278 | 0.95 | SIK2 (0.91) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL21479253 | 0.94 | SIK2 (0.88) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL22337166 | 0.93 | SIK2 (0.86) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL25315123 | 0.92 | SIK2 (0.85) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL30439431 | 0.92 | SIK2 (0.85) | SIK2CSF1RSIK1SIK3TNK2 | |
| SCHEMBL25972187 | 0.92 | SIK2 (0.85) | SIK2CSF1RSIK1SIK3TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3481830-B1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | BROAD INST INC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210147425-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE BROAD INSTITUTE, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | SIK2 1/4885CSF1R 3749/4885SIK1 2/4885 |
| US-20200253981-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | SIK2 1/4885CSF1R 3749/4885SIK1 2/4885 |
| US-20210147425-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | SIK2 2/4885CSF1R 4501/4885SIK1 1/4885 |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | SIK2 2/4885CSF1R 6/4885SIK1 3/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | SIK2 2/4885CSF1R 6/4885SIK1 3/4885 |
| US-20200317675-A9 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | SIK2 2/4885CSF1R 4476/4885SIK1 1/4885 |
| US-20190315752-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | SIK2 2/4885CSF1R 4476/4885SIK1 1/4885 |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | SIK2 116/4885CSF1R 28/4885SIK1 97/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | SIK2 2/4885CSF1R 6/4885SIK1 3/4885 |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | SIK2 2/4885CSF1R 4476/4885SIK1 1/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | SIK2 2/4885CSF1R 4476/4885SIK1 1/4885 |
| US-10954242-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | SIK2 2/4885CSF1R 4476/4885SIK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.